Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Trial Parameters
Brief Summary
Exploring the precise medicine of patients with primary hepatobiliary cancer. And evaluate the efficacy and safety of individualized treatment regimens for primary hepatobiliary cancer based on next-generation sequencing.
Eligibility Criteria
Inclusion Criteria: 1. Age from 18 to 65, male or female. 2. Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV. 3. Palliative care as the preferred. 4. The result of next-generation sequencing (NGS) test show the patient has gene mutation and also can be treated by the right commercial products that have been approved by the China Food and Drug Administration (CFDA) or the Food and Drug Administration (FDA). 5. ECOG performance status 0-2. 6. Life expectancy ≥3 months. 7. Agree to sign informed consent form. Exclusion Criteria: 1. Hepatobiliary cancer patient with stageI-III, or with any of the following items will not be eligible for screening. Such as, suitable for the treatment of radical resection, radical resection but evaluation unmeasurable. 2. The result of NGS test show the patient has no gene mutation, or has gene mutation but no medicine. 3. ECOG performance status ≥ 3. 4. Female patients who are pregnant or not using a contraceptive method o